INR Advisory Services’s Invesco Pharmaceuticals ETF PJP Stock Holding History

INR Advisory Services’s Portfolio PJP Stock Details PJP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$1K	Hold	17	–	–	﹤0.01%	69
2018 Q4	$1K	Buy	+17	New	+$1.15K	﹤0.01%	69

Other funds holding PJP

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

PAM

Peak Asset Management Louisville, Colorado $680M AUM 22.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

INR Advisory Services's PJP Position: Q1 2019 in Review

INR Advisory Services held its Invesco Pharmaceuticals ETF (PJP) position steady in Q1 2019 at 17 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #69.

INR Advisory Services first reported a position in PJP in Q4 2018 and has held it in 2 quarters since. 95 funds tracked by Wall St. Rank hold PJP as of Q1 2019.

INR Advisory Services held 17 shares of Invesco Pharmaceuticals ETF worth $1K as of Q1 2019.
INR Advisory Services left its Invesco Pharmaceuticals ETF share count unchanged in Q1 2019.
Invesco Pharmaceuticals ETF made up ﹤0.01% of INR Advisory Services's portfolio in Q1 2019, its #69 holding.
INR Advisory Services first reported a position in Invesco Pharmaceuticals ETF in Q4 2018 and has held it in 2 quarters since.
95 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q1 2019.

Based on INR Advisory Services's 13F filing for Q1 2019, filed 22 Apr 2019.